Irinotecan and Leucovorin-Modified 5-Fluorouracil for Elderly Colorectal Cancer Patients
Author Information
Author(s): Comella P, Farris A, Lorusso V, Palmeri S, Maiorino L, Lucia L De, Buzzi F, Mancarella S, Vita F De, Gambardella A
Primary Institution: National Tumour Institute, Naples, Italy
Hypothesis
Can irinotecan plus leucovorin-modulated 5-fluorouracil be a suitable treatment for elderly patients with metastatic colorectal carcinoma?
Conclusion
The study suggests that irinotecan plus leucovorin-modulated 5-fluorouracil is a feasible treatment option for elderly patients with metastatic colorectal cancer.
Supporting Evidence
- The IRIFAFU regimen produced an overall response rate of 36%.
- Median progression-free survival was 7.4 months for younger, 8.0 months for middle-aged, and 5.3 months for elderly patients.
- Severe toxicity was not greater in elderly patients compared to younger patients.
Takeaway
Doctors found that a special combination of medicines can help older people with a type of cancer called colorectal cancer, and it seems to work well for them.
Methodology
Patients with metastatic colorectal cancer were randomly assigned to receive the IRIFAFU regimen, and their responses and side effects were analyzed based on age groups.
Potential Biases
Potential selection bias due to reluctance of caregivers to refer elderly patients for treatment.
Limitations
The study was retrospective and not powered to reveal significant differences according to age, and there was a lack of data on associated diseases.
Participant Demographics
Patients were divided into three age groups: younger (≤54 years), middle-aged (55–69 years), and elderly (≥70 years).
Statistical Information
Confidence Interval
95% confidence interval, 28–44%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website